NK-611 is an epipodophyllotoxin derivative. NK-611 induces DNA double-strand breaks by inhibiting topoisomerase II (IC50 = 56 μM). NK-611 does not inhibit microtubule polymerization, thus avoiding the side effects of the parent compound, Podofilox. NK-611 exhibits broad-spectrum antitumor activity and demonstrates potent efficacy in in vivo models of leukemia. NK-611 can be used in cancer research.

F-14512 hydrochloride is an anticancer agent that utilizes the polyamine transport system (PTS) to selectively deliver polyamine-containing drugs to cancer cells. F-14512 hydrochloride enhances the affinity of polyamines for DNA, thereby inhibiting topoisomerase II and achieving selective cellular uptake. F-14512 hydrochloride exhibits significant cytotoxicity against cells with high PTS activity and induces DNA damage. F-14512 hydrochloride demonstrates potent antitumor activity in the MX1 breast tumor xenograft model. F-14512 hydrochloride could be used to study breast cancer.

GI-149893 is a selective topoisomerase I (TopoI) inhibitor. GI-149893 prevents DNA religation and induces irreversible DNA damage in tumor cells. GI-149893 is promising for research of cancers (e.g., colon carcinoma HT-29/SW-48, breast MX-1, prostate PC-3 xenografts).

Chlorozotocin (NSC 178248) is a glucose-based chloroethylnitrosourea with low myelotoxicity for studying leukemia in mice.

YM-534, an imidazole compound, is an anti-cancer agent. YM-534 inhibits HL-60 cells with an IC50 of 2.5 μM. YM-534 retards the processing of preribosomal to ribosomal RNA of HL-60 cells. YM-534 can be used for the study of promyelocytic leukemia.

WRN inhibitor 20 (Compound 14c) is a WRN degradation agent. WRN inhibitor 20 exhibits strong degradation activity in various cells, such as HCT-116 (DC50 = 1.7 µM), SW-48 (DC50 = 3.0 µM), and SW-480 (DC50 = 5.9 µM) cells. WRN inhibitor 20 exhibits potent anti proliferative, pro apoptotic, migration inhibiting, and DNA damage inducing effects in MSI-H cells. WRN inhibitor 20 can be used for research on cancer.

TBIA (trans bis-isatoic anhydride) is a covalent RNA crosslinker. TBIA selectively induces RNA tertiary interactions (e.g., multi-helix junctions, loop-helix packing). TBIA is promising for research of RNA higher-order structure and disease-associated RNAs (e.g., KRAS-mutant RNAs).

AGM-130 is a cyclin-dependent kinase (CDK) inhibitor. AGM-130 exhibits antitumor activity.

LP-661438 (Compound 10) is an orally active DCK inhibitor (IC50 = 1.7 nM). LP-661438 inhibits deoxycytidine kinase in T cells and in vivo.

Aurora kinase inhibitor-14 (Compound 79) is an orally active and highly selective inhibitor of Aurora kinases with IC50 values of 0.5 nM and 1.2 nM for Aurora A and Aurora B, respectively. Aurora kinase inhibitor-14 binds to the ATP-binding site of Aurora kinases to block chromosome segregation during mitosis and induce apoptosis in tumor cells. Aurora kinase inhibitor-14 is promising for research of various solid tumors and hematological malignancies, such as non-small cell lung cancer, breast cancer, and acute myeloid leukemia.

KD025m1 is a novel selective ROCK2 inhibitor. KD025m1 has good anti obesity, improved insulin sensitivity, and blood glucose control effects. KD025m1 can be used to study metabolic diseases such as diabetes and obesity.

PNU-142586 is the major metabolite of Linezolid. PNU-142586 can inhibit the activity of DNA topoisomerase 2-α (TOP2A) and DNA topoisomerase 2-β (TOP2B). PNU-142586 interferes with DNA replication and transcription by blocking the binding of DNA to TOP2 and inhibiting ATP hydrolysis. PNU-142586 can be used to study Linezolid-induced hematotoxicity and its molecular mechanism.

LO-3-63, a Ribociclib analog bearing a truncated fumaramide handle, is a PROTAC-like CDK4/6 degrader. LO-3-63 induces CUL4DCAF16-dependent degradation of CDK4/6 in cells.

KWZY-11 (Compound 11) is a potent PARP/CDK6 dual inhibitor with IC50 values of 156.8, 197.3, and 13.3 nM for PARP1, PARP2, and CDK6, respectively. KWZY-11 inhibits tumor cell proliferation by regulating the Wnt/β-catenin signaling pathway. KWZY-11 induces excessive DNA damage and apoptosis in MDA-MB-231 breast cancer cells.

MRL-436 is a RNA polymerase inhibitor with antibacterial activity. MRL-436 exerts its antibacterial activity dependent on residue 622 of the RNA polymerase β' subunit and the RNAP ω subunit. MRL-436 inhibits Rifampicin-resistant RNA polymerase derivatives and exhibits antibacterial activity against Rifampicin-resistant strains.

Pyridostatin (RR82) trihydrochloride is a G-quadruplex DNA stabilizing agent (Kd=490 nM) and can target DNA and RNA G4s in cells. Pyridostatin trihydrochloride promotes growth arrest in human cancer cells by inducing replication- and transcription-dependent DNA damage. Pyridostatin trihydrochloride targets the proto-oncogene Src. Pyridostatin trihydrochloride reduced SRC protein levels and SRC-dependent cellular motility in human breast cancer cells.

C791-0064 is a RAD52 inhibitor. C791-0064 specifically binds to RAD52 and disrupts its single-strand annealing activity. C791-0064 specifically inhibits the proliferation of cancer cells with BRCA2 deficiency, inducing DNA damage and apoptosis (apoptosis). C791-0064 can be used for the study of BRCA mutation-related cancers (such as breast cancer and ovarian cancer).

G923-0271 is a TDP-43 protein inhibitor. G923-0271 can be used for the research of neurological disease, such as Alzheimer's Disease.

AG-12275 is a cyclin-dependent kinase (CDK) inhibitor. AG-12275 can be used for the research of cancer.

MDI-117740 is a dual LIMK1/2 inhibitor. MDI-117740 shows effective cellular target engagement with LIMK1 (pIC50 = 6.73) and LIMK2 (pIC50 = 7.18) in HEK293 cells. MDI-117740 exerts significant anti-migratory activity in MDA-MB-231 cells. MDI-117740 can be used for the study of diseases associated with LIMK dysregulation, such as cancers and neurodegenerative disorders.

MGB1Y is a noncovalent DNA minor groove binder (MGB). MGB1Y potently inhibits cancer cells proliferation and topoisomerase I activity. MGB1Y downregulates their breast cancer-related genes in MCF7 and MDA-MB-231 cells. MGB1Y has a broad-spectrum anticancer activity, such as breast cancer, colon cancer, and leukemia.

MGB4 is a DNA minor groove binder. MGB4 binds to ARE-containing DNA and inhibition of topoisomerase I activity. MGB4 can impacts key cellular pathways, including inhibition oftranslation and alterations in sphingolipid and amino acid metabolism. MGB4 also reduces spermine and spermidine metabolism companied with Doxorubicin). MGB4 can be used for the research of cancer, such as Prostate cancer.

Ara-UTP is a sugar-modified nucleotide triphosphate that deceives RNA polymerases and blocks chain extension.

LD2-3 is a topoisomerase I inhibitor. LD2-3 can be connected to monoclonal antibodies via linkers to form antibody-drug conjugate (ADC) molecules. LD2-3 can be coupled with CEA antibodies to form ADC drugs for the study of CEA overexpressing tumors.

NU1064 (dihydrochloride) is an inhibitor of PARP. NU1064 (dihydrochloride) potentiates the cytotoxicity of DNA-methylating agent (MTIC) in a concentration-dependent manner.

(±)-Dehydroaltenusin, an antibiotic, is a selective eukaryotic DNA polymerase α (pol α) inhibitor with an IC50 of 0.68 μM. (±)-Dehydroaltenusin can be isolated from fungus Alternaria tenuis. (±)-Dehydroaltenusin competitively inhibits the DNA template primer (Ki: 0.23 μM) and non-competitively suppresses the 2'-deoxyribonucleoside 5'-triphosphate substrate (Ki: 0.18 μM). (±)-Dehydroaltenusin induces the cancer cell S-phase cycle arrest and apoptosis. (±)-Dehydroaltenusin can be used for cancers like human adenocarcinoma research.

i-AZD1775 (TFA) is an immobilizable analogue of AZD1775. i-AZD1775 (TFA) retains the ability to inhibit WEE1 in vitro. i-AZD1775 (TFA) can be studied in anticancer research.

YH-0623 is an orally active mitochondrial RNA polymerase (POLRMT) inhibitor (IC50 = 50.48 nM, Nanoluciferase Bioluminescence Resonance Energy Transfer (NanoBRET) assay). YH-0623 exhibits antiproliferative effects on 22Rv1 cells by reducing the expression of mitochondrial-related genes. YH-0623 inhibits 22Rv1 cell growth, colony formation, and the expression of OXPHOS-related proteins. YH-0623 significantly inhibits tumor growth in a prostate cancer xenograft mouse model. YH-0623 is indicated for prostate cancer research.

Cyanine 3-dCTP is a Cy3-labeled nucleotide and can be used for DNA synthesis.

5-Iodo-dCTP is a good substrates for DNA polymerases and can be used for DNA synthesis.